Sizzling Stock Picks

[whatisthecolorofmone]

$LPCN Updated corporate presentation

http://files.shareholder.com/downloads/AMDA-2BVSIV/865335907x0x854540/02A0C183-90F8-4111-9DFD-53EF25A00674/LPCN_Presentation_October_FINAL.pdf


Highlights

First oral testosterone replacement option
– Targeting ~ $2.0 Billion TRT market
– NDA submitted August 2015
– Differentiated from existing products
Orphan designated oral alternative for the prevention of preterm birth
– Avoids painful injections of the only FDA approved intra-muscular drug
– Multi-dose PK study expected to start 4Q 2015
Strong Balance Sheet
– Over $53M in Cash as of June 30th – Sufficient to last past LPCN 1021 anticipated
PDUFA date
– No Debt